2022
Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study
Cox H, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A, Mohr-Holland E, Daniels J, Cudahy PGT, Nicol MP, Borrell S, Reinhard M, Doetsch A, Beisel C, Gagneux S, Warren RM, Furin J. Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study. Journal Of Clinical Microbiology 2022, 60: e02362-21. PMID: 35170980, PMCID: PMC8925891, DOI: 10.1128/jcm.02362-21.Peer-Reviewed Original ResearchConceptsDrug susceptibility testingRifampicin-resistant tuberculosisShort regimenMDR/RR-TB patientsMDR/RR-TBRR-TB patientsRetrospective cohort studyMore effective treatment regimensHigh-burden settingsRoutine drug susceptibility testingTB drug resistanceEffective treatment regimensWhole-genome sequencingTolerable regimensCohort studyRetrospective cohortRR-TBRegimen changeTreatment regimensTreatment recommendationsPatient outcomesTreatment individualizationClinical dataIndividualized treatmentIneffective drugsPhylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis
Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, Chitwood MH, Alexandru S, Bivol S, Russi M, Havumaki J, Cudahy P, Fosburgh H, Allender CJ, Centner H, Engelthaler DM, Menzies NA, Warren JL, Crudu V, Colijn C, Cohen T. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLOS Medicine 2022, 19: e1003933. PMID: 35192619, PMCID: PMC8903246, DOI: 10.1371/journal.pmed.1003933.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisDrug-resistant M. tuberculosisM. tuberculosis strainsPutative transmission clustersM. tuberculosisTransmission clustersMultidrug-resistant M. tuberculosis strainsTuberculosis strainsMultiple M. tuberculosis strainsCulture-positive TB casesLocal transmissionMDR-TB epidemicDrug-susceptible tuberculosisDrug resistance mutationsDrug resistance profilesUrgency of interventionTB casesDemographic dataNew casesTuberculosisInadequate treatmentNatural historyResistance mutationsBeijing lineageMycobacterium tuberculosis
2021
Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S, Reinhard M, Doetsch A, Cudahy PGT, Mohr-Holland E, Daniels J, Dippenaar A, Nicol MP, Gagneux S, Warren RM, Cox H. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00364-21. PMID: 34460307, PMCID: PMC8522772, DOI: 10.1128/aac.00364-21.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBRMR-TBRR-TBPatient-level clinical dataPhenotypic drug susceptibility testingRifampicin-monoresistant tuberculosisRR-TB patientsMultidrug-resistant tuberculosisHIV-positive individualsRifampin-resistant tuberculosisDrug susceptibility testingRifampin monoresistanceHIV infectionMDR isolatesTB drugsRisk factorsClinical dataSusceptibility testingSubset of isolatesTuberculosisDescriptive studyMycobacterium tuberculosisAvailable WGS dataSignificant differencesPatients
2020
Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study
Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases 2020, 20: 789. PMID: 33097000, PMCID: PMC7585300, DOI: 10.1186/s12879-020-05515-4.Peer-Reviewed Original ResearchConceptsM. tuberculosis infectionRecurrent tuberculosisSuccessful treatmentTuberculosis recurrenceHazard ratioSmear gradeTuberculosis infectionRisk factorsSmear-positive pulmonary tuberculosisCox proportional hazards modelSputum smear gradeRepetitive unit-variable number tandem repeat (MIRU-VNTR) typingHigh-burden settingsRisk of recurrenceProportional hazards modelSuccessful treatment completionRecurrent diseaseCohort studyPulmonary tuberculosisBurden settingsClinical presentationRecurrent episodesInitial episodeNumber tandem repeat typingTreatment completion
2018
Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogen
2017
Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis
Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. European Respiratory Journal 2017, 49: 1601075. PMID: 28100546, PMCID: PMC5898952, DOI: 10.1183/13993003.01075-2016.Peer-Reviewed Original ResearchConceptsLine probe assayComposite reference standardINH resistanceRIF resistanceSystematic reviewMultidrug-resistant tuberculosis (MDR-TB) casesRapid drug susceptibility testingMultidrug-resistant tuberculosisProbe assayTuberculosis detectionDrug susceptibility testingSmear-positive specimensSmear-negative specimensReference standardM. tuberculosis detectionMycobacterium tuberculosis detectionPulmonary TBTuberculosis casesNew line probe assayStudy qualityIsoniazid resistanceQUADAS-2Indirect testingRifampicinUnique studies